What Is the Normal Size of a Prostate at Age 70?

Prostate size at age 70 is highly variable. Learn what defines the typical range, how it’s measured, and the context of age-related changes.

A prostate gland in a 70-year-old man typically measures somewhere around 30 to 40 milliliters, though the range across healthy individuals is wide. In younger adults the prostate is roughly the size of a walnut, about 20 mL or so, but it grows steadily throughout life and picks up speed after the late forties. That growth pattern means there is no single “normal” number at 70, and a prostate that measures 35 mL and one that measures 50 mL can both belong to men with no urinary complaints at all.

How the Prostate Grows With Age

A large study of asymptomatic men found that mean prostate volume rises in a non-linear curve, starting at about 18.7 mL around age 18 and reaching roughly 41.3 mL by age 89. Growth accelerates noticeably after about age 49, jumping from a pace of around 0.10 mL per year in young adulthood to about 0.68 mL per year in the oldest age groups. Longitudinal data from the Baltimore Longitudinal Study of Aging puts the overall median growth at about 0.6 mL per year, or roughly a 2.5% annual increase. A separate community-based study of men aged 40 to 79 estimated the average annual change at about 1.6%, with bigger prostates growing faster than smaller ones.

If you start with a 25 mL gland at age 50 and apply a growth rate of roughly 0.6 mL per year, you land somewhere around 37 mL by 70. But individual variation is enormous. Some men barely grow at all; others add several milliliters a year. What matters clinically is less the raw volume and more what part of the gland is growing and whether it’s pressing on the urethra.

Which Part of the Gland Actually Gets Bigger

The prostate isn’t a uniform ball of tissue. It has distinct zones, and they don’t all grow at the same rate. The transition zone, the innermost ring that surrounds the urethra, is the region responsible for most age-related enlargement. Research on zonal growth patterns found that the transition zone grows continuously throughout life without plateauing, while the peripheral zone (the outer portion, where most cancers arise) grows more slowly and peaks between ages 60 and 70. A study of age-related growth by ultrasound confirmed that transition zone measurements showed the most dramatic differences after age 50, with the fastest rate of increase occurring between ages 50 and 69.

This is why two prostates of the same total volume can produce completely different experiences. A gland that is 40 mL but has most of its bulk in the peripheral zone may leave the urethra relatively unobstructed. A 35 mL gland with most of its growth concentrated in the transition zone can squeeze the urethra enough to cause a weak stream, frequent nighttime trips to the bathroom, and a feeling of incomplete emptying.

How Prostate Size Is Measured

You might wonder how your doctor arrives at a volume number. The two most common imaging methods are transrectal ultrasound (TRUS) and MRI. Both use a formula that treats the prostate as an ellipsoid and calculates volume from three dimensions. Comparisons against the gold standard of surgically removed specimens show that MRI tends to be slightly more accurate overall, coming within about 0.56 mL of the actual specimen volume on average, while TRUS underestimates by about 4.5 mL. That said, the two methods generally agree reasonably well in practice, with a strong correlation between MRI and TRUS volumes.

There is also the digital rectal exam, the gloved-finger check that has been part of prostate screening for decades. It gives a rough sense of size and shape, but it correlates poorly with actual prostate weight. One study comparing DRE estimates to surgical specimens found a weak correlation, while TRUS correlated moderately well. The practical upshot: if your doctor says your prostate “feels a little large” on a DRE, that’s a useful screening observation, but it isn’t a precise measurement. Imaging gives you the number.

Bigger Does Not Always Mean More Symptoms

One of the most persistent misconceptions about prostate enlargement is that a bigger gland automatically means worse urinary problems. The reality is that the correlation between total prostate volume and symptom severity is surprisingly weak. A study examining this relationship in men with benign prostatic hyperplasia found only a weak positive link between prostate volume and scores on the International Prostate Symptom Score. Another study found a statistically significant but still modest correlation between volume and symptom scores, along with a modest negative relationship between volume and peak urinary flow rate.

What seems to matter more than sheer volume is how much the prostate protrudes into the bladder. Research on intravesical prostatic protrusion, the portion of gland that bulges upward past the bladder floor, found that the volume of that protrusion was an independent predictor of reduced urinary flow and increased residual urine left in the bladder after voiding. So a man with a modestly enlarged gland that juts upward into the bladder can have more trouble than someone with a larger gland that stays below the bladder floor.

The bladder itself also adapts, and not always for the better. When the prostate blocks outflow over a long period, the bladder wall undergoes structural changes. Muscle cells respond to the constant stretching by altering how they contract, building up extra tissue, and eventually losing some of their ability to squeeze effectively. This is part of why urologists don’t wait for the prostate to hit some magic volume before discussing treatment. The longer the bladder strains against obstruction, the harder it becomes to recover normal function.

How Common Is an Enlarged Prostate at 70

By age 70, benign prostatic hyperplasia is less an exception and more the default. Roughly 80% of men over 70 have some degree of BPH, up from about 45% among men over 45. That doesn’t mean 80% of 70-year-old men are suffering. Many have mild or no symptoms, and the diagnosis itself is partly anatomical. The gland is just larger than the textbook cutoff, often defined around 30 mL, without necessarily causing clinical trouble.

PSA and Prostate Volume

PSA, the blood test most men know from cancer screening, is also closely linked to prostate size in benign cases. A cross-sectional study found a strong positive correlation between serum PSA and prostate volume in men with benign enlargement, with rising PSA levels largely reflecting leakage from more glandular tissue rather than cancer. This means a 70-year-old man with a 45 mL prostate will, on average, have a higher PSA than a man the same age with a 25 mL gland, even if neither has cancer.

This is where PSA density becomes useful. PSA density is simply your PSA level divided by your prostate volume. A larger gland naturally produces more PSA, so dividing by volume adjusts for that. Research shows that PSA density is significantly better than raw PSA at distinguishing benign enlargement from cancer, particularly when PSA falls in the ambiguous range between 2 and 4 ng/mL. One study found that a PSA density cutoff of about 0.13 ng/mL per mL of prostate volume could identify candidates for biopsy with both sensitivity and specificity above 90%. If your PSA is mildly elevated and your prostate is large, your doctor may conclude the PSA is simply tracking your gland size. If the same PSA number came from a smaller gland, it would be more concerning.

What Makes Some Prostates Grow Faster

Genetics plays a role, and some of the variation shows up along ethnic and geographic lines. A study among different ethnic groups in the Democratic Republic of Congo found striking differences: the median prostate size in Lega men was 55 mL with 91% having enlarged prostates, while Havu men had a median of just 20 mL and only 11% were enlarged. In the United States, a large study of health professionals found that after adjusting for age, body mass index, and lifestyle factors, Black and Asian men were not at clearly increased risk for BPH compared with white men, and Asian men actually trended toward slightly lower risk. Men of southern European ancestry showed a modestly elevated risk.

Beyond genetics, metabolic health is a significant driver. A systematic review and meta-analysis found that metabolic syndrome, the cluster of conditions including central obesity, high blood sugar, and abnormal cholesterol, is associated with prostate enlargement. The proposed mechanism involves elevated insulin levels ramping up sympathetic nerve activity, which in turn stimulates prostatic growth. A study comparing prostate growth rates in men with and without metabolic syndrome found that the metabolic-syndrome group had a median annual total prostate growth of 1.0 mL per year versus 0.64 mL per year in men without it. Keeping your weight, blood sugar, and blood pressure in check won’t stop the prostate from growing, but it may slow the pace.

When Treatment Enters the Picture

There is no hard threshold at which prostate size alone triggers treatment. Guidelines take volume into account primarily because it helps determine which procedures are options. Some surgical techniques work well for small-to-medium glands but not for very large ones, and vice versa. The American Urological Association’s surgical guidelines use a size-based algorithm, categorizing prostates as “average” or “large” to match patients to appropriate procedures.

For men whose symptoms are bothersome but not severe enough for surgery, medications called 5-alpha-reductase inhibitors can shrink the gland. Finasteride and dutasteride are the two main options. A real-world retrospective study found that dutasteride achieved a greater reduction in prostate volume (about 26% versus 18% for finasteride) and a slightly larger improvement in symptom scores. However, a five-year retrospective analysis found that the two drugs produced similar long-term results in symptom scores, flow rate, and volume reduction, though dutasteride was associated with more sexual side effects and breast-related complications. The choice between them is something to discuss with a urologist, factoring in your prostate size, symptom severity, and tolerance for side effects.

Saw Palmetto and Other Supplements

Walk through any pharmacy and you’ll see saw palmetto supplements marketed for prostate health. The extract, from the berries of the Serenoa repens palm, has been studied for decades. Laboratory research suggests several potential mechanisms, including inhibition of the same 5-alpha-reductase enzyme that prescription drugs target, along with anti-inflammatory effects. A randomized, placebo-controlled trial found that a formulation enriched with beta-sitosterol (a plant sterol found in saw palmetto) led to significant improvements in symptom scores and reductions in residual urine volume and PSA over 12 weeks compared with placebo.

The clinical evidence on saw palmetto overall remains mixed, though. Several large, well-designed trials have failed to show a clear benefit over placebo, and major urology guidelines do not recommend it as a first-line treatment. Some men swear by it, and it’s generally considered safe, but the honest summary is that the evidence isn’t strong enough to promise results. If you try it, treat it as a complementary option alongside medical follow-up rather than a substitute for it.

Ethnic Variation in “Normal”

One underappreciated point is that population-level data on prostate size comes disproportionately from studies of white men in North America and Europe. As the data from the Congo illustrates, prostate volumes can differ dramatically between ethnic groups even within the same geographic region. The threefold difference between Lega and Havu men, living in the same province, is far larger than any age-related growth within one population. It’s a reminder that the “30 to 40 mL” figure commonly cited for a 70-year-old reflects a specific population average and may not accurately describe normal for every man. Genetic background, diet, metabolic health, and possibly environmental exposures all influence where any individual lands on the spectrum. If your doctor gives you a prostate volume number, the meaningful question isn’t whether it matches a population average. It’s whether the gland is causing obstruction, whether it’s growing unusually fast, and whether any action would improve your quality of life.